Related Experiment Video
Updated: Oct 1, 2026
Chromosome Preparation From Cultured Cells
Published on: January 28, 2014
Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia
A Zaccaria1, G Rosti, N Testoni
1Institute of Hematology Lorenzo e Ariosto Sergnoli, University of Bologna, Italy.
Insights
Allogeneic bone marrow transplants for chronic myeloid leukemia may not eradicate all Ph1+ cells. Residual leukemia cells are controlled by immune mechanisms, suggesting new therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Allogeneic bone marrow transplantation (BMT) is a curative option for Philadelphia chromosome-positive (Ph1+) chronic myeloid leukemia (CML).
- Complete eradication of leukemic cells and full donor chimerism are traditionally considered essential for cure.
Purpose of the Study:
- To investigate the persistence of Ph1+ cells after BMT for CML.
- To explore the role of immune mechanisms in controlling residual CML.
- To evaluate immunomodulatory strategies in managing residual CML.
Main Methods:
- Cytogenetic and molecular analyses to detect Ph1+ cells post-BMT.
- Evaluation of outcomes in patients receiving T-cell depleted marrow.
- Assessment of therapeutic strategies like cyclosporin-A discontinuation and alpha interferon.
Main Results:
- Ph1+ cells frequently persist long-term after chemo-radiotherapy conditioning in BMT for CML.
- Immune mechanisms appear crucial for controlling and reducing residual Ph1+ cell populations.
- Immunomodulatory therapies can reduce Ph1+ cell burden even in relapsed cases.
Conclusions:
- Complete elimination of Ph1+ cells is not always achieved with current BMT conditioning.
- Immune surveillance plays a vital role in managing residual CML post-transplant.
- Targeting immune mechanisms offers potential for treating residual CML and preventing relapse.
Abstract:
Allogeneic bone marrow transplantation is the only way to cure patients with Ph1+ chronic myeloid leukemia. It is commonly assumed that, in order to obtain a cure for the patients, the leukemic clone must be completely destroyed by the conditioning treatment and the donor's bone marrow must repopulate the hemopoietic niches leading to a "complete chimera". However, cytogenetic analyses, supported by molecular ones, indicate that Ph1+ cells, far from being completely destroyed by chemo-radiotherapy may persist for a long time, probably in the majority of the patients. As demonstrated by the outcome of patients receiving T-cell depleted marrow, immune mechanisms must be involved in controlling and progressively reducing the size of the residual leukemic clone. Furthermore, immunodulating therapeutic strategies, represented by cyclosporin-A discontinuation or alpha interferon treatment, may successfully reduce the Ph1+ cell population even after a full relapse.
